Sleepiness, inflammation and oxidative stress markers in middle-aged males with obstructive sleep apnea without metabolic syndrome: a cross-sectional study

Respiratory Research

Sônia Maria Togeiro³  Sergio Tufik³  Sônia Hix¹  Gláucia Carneiro²  Vânia D’Almeida⁴  Daniela Kuguimoto Andaku³ 

[1] Department of Morphology and Physiology, Faculdade de Medicina do ABC–FUABC, Santo André, SP, Brazil;Department of Medicine, Universidade Federal de São Paulo (UNIFESP-EPM), São Paulo, SP, Brazil;Department of Psychobiology, Universidade Federal de São Paulo (UNIFESP-EPM), São Paulo, SP, Brazil;Rua Napoleão de Barros, 925, São Paulo, CEP 04024-002, SP, Brazil

关键词: Oxidative stress;    C- reactive protein;    Inflammation;    Metabolic syndrome;    Excessive daytime sleepiness;    Obstructive sleep apnea;   

Others  :  1135925
DOI  :  10.1186/s12931-015-0166-x

 received in 2014-09-12, accepted in 2015-01-05,  发布年份 2015

【 摘 要 】

Background

The simultaneous occurrence of metabolic syndrome and excessive daytime sleepiness are very common in obstructive sleep apnea (OSA) patients. Both conditions, if present in OSA, have been reported to be associated with inflammation and disruption of oxidative stress balance that impair the cardiovascular system. To verify the impact of daytime sleepiness on inflammatory and oxidative stress markers, we evaluated OSA patients without significant metabolic disturbance.

Methods

Thirty-five male subjects without diagnostic criteria for metabolic syndrome (Adult Treatment Panel III) were distributed into a control group (n = 10) (43 ± 10.56 years, apnea-hypopnea index - AHI 2.71 ± 1.48/hour), a non-sleepy OSA group (n = 11) (42.36 ± 9.48 years, AHI 29.48 ± 22.83/hour) and a sleepy OSA group (n = 14) (45.43 ± 10.06 years, AHI 38.20 ± 25.54/hour). Excessive daytime sleepiness was considered when Epworth sleepiness scale score was ≥ 10. Levels of high-sensitivity C-reactive protein, homocysteine and cysteine, and paraoxonase-1 activity and arylesterase activity of paraoxonase-1 were evaluated.

Results

Patients with OSA and excessive daytime sleepiness presented increased high-sensitivity C-reactive protein levels even after controlling for confounders. No significant differences were found among the groups in paraoxonase-1 activity nor arylesterase activity of paraoxonase-1. AHI was independently associated and excessive daytime sleepiness tended to have an association with high-sensitivity C-reactive protein.

Conclusions

In the absence of metabolic syndrome, increased inflammatory response was associated with AHI and daytime sleepiness, while OSA was not associated with abnormalities in oxidative stress markers.

【 授权许可】

   
2015 Andaku et al.; licensee BioMed Central.

【 参考文献 】

• [1]Lavie P, Herer P, Hoffstein V: Obstructive sleep apnoea syndrome as a risk factor for hypertension: population study. BMJ 2000, 320:479-82.
• [2]Peppard PE, Young T, Palta M, Skatrud J: Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 2000, 342:1378-84.
• [3]Shahar E, Whitney CW, Redline S, Lee ET, Newman AB, Javier Nieto F, et al.: Sleep-disordered breathing and cardiovascular disease – cross-sectional results of the Sleep Heart Health Study. Am J Respir Crit Care Med 2001, 163:19-25.
• [4]Cintra F, Tufik S, D’Almeida V, Calegare BFA, Paola A, Oliveira W, et al.: Cysteine – a potential biomarker for obstructive sleep apnea. Chest 2011, 139:246-52.
• [5]Sharma SK, Mishra HK, Sharma H, Goel A, Sreenivas V, Gulati V, et al.: Obesity, and not obstructive sleep apnea, is responsible for increased serum hs-CRP in patients with sleep-disorderd breathing in Delhi. Sleep Med 2008, 9:149-56.
• [6]Kritikou I, Basta M, Vgontzas AN, Pejovik S, Liao D, Tsaoussoglou M, et al.: Sleep apnoea, sleepiness, inflammation and insulin resistance in middle-aged males and females. Eur Respir J 2014, 43:145-55.
• [7]Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al.: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific statement. Circulation 2005, 112:2735-52.
• [8]Drager LF, Lopes HF, Maki-Nunes CM, Trombetta IC, Toschi-Dias E, Alves MJNN, et al.: The impact of obstructive sleep apnea on metabolic and inflammatory markers in consecutive patients with metabolic syndrome. PLoS One 2010, 5:e12065. doi: 10.1371/journal.pone.0012065
• [9]Shiina K, Tomiyama H, Takata Y, Usui Y, Asano K, Hirayama Y, et al.: Concurrent presence of metabolic syndrome in obstructive sleep apnea syndrome exacerbates the cardiovascular risk: a sleep clinic cohort study. Hypertens Res 2006, 29:433-41.
• [10]Bonsignore MR, Esquinas C, Barceló A, Sanchez-de-la-Torre M, Paternó A, Duran-Cantolla J, et al.: Metabolic syndrome, insulin resistance and sleepiness in real-life obstructive sleep apnoea. Eur Respir J 2012, 39:1136-43.
• [11]Trombetta IC, Somers VK, Maki-Nunes C, Drager LF, Toschi-Dias E, Alves MJNN, et al.: Consequences of comorbid sleep apnea in the metabolic syndrome – implications for cardiovascular risk. Sleep 2010, 33:1193-9.
• [12]Drager LF, Bortolotto LA, Maki-Nunes CM, Trombetta IC, Alves MJNN, Fraga RF, et al.: The incremental role of obstructive sleep apnea on markers of atherosclerosis in patients with metabolic syndrome. Atherosclerosis 2010, 208:490-5.
• [13]Ryan S, Taylor CT, McNicholas WT: Systemic inflammation: a key factor in the pathogenesis of cardiovascular complications in obstructive sleep apnoea syndrome? Thorax 2009, 64:631-6.
• [14]Agrawal S, Sharma SK, Sreenivas V, Lakshmy R, Mishra HK: Stepped approach for prediction of syndrome Z in patients attending sleep clinic: a north Indian hospital-based study. Sleep Breath 2012, 16:621-7.
• [15]Kapur VK, Resnick HE, Gottlieb DJ: Sleep disordered breathing and hypertension: does self-reported sleepiness modify the association? Sleep 2008, 31:1127-32.
• [16]Lombardi C, Parati G, Cortelli P, Provini F, Vetrugno R, Plazzi G, et al.: Daytime sleepiness and neural cardiac modulation in sleep-related breathing disorders. J Sleep Res 2008, 17:263-70.
• [17]Ronksley PE, Hemmelgarn BR, Heitman SJ, Hanly PJ, Faris PD, Quan H, et al.: Obstructive sleep apnoea is associated with diabetes in sleepy subjects. Thorax 2009, 64:834-9.
• [18]Nena E, Steiropoulus P, Papanas N, Tsara V, Fitili C, Froudarakis ME, et al.: Sleepiness as a marker of glucose deregulation in obstructive sleep apnea. Sleep Breath 2012, 16:181-6.
• [19]Barceló A, Barbé F, de la Peña M, Maartinez P, Soriano JB, Piérola J, et al.: Insulin resistance and daytime sleepiness in patients with sleep apnoea. Thorax 2008, 63:946-50.
• [20]Vgontzas AN, Papanicolau DA, Bixler EO, Kales A, Tyson K, Chrousos GP: Elevation of plasma cytokines in disorders of excessive daytime sleepiness: role of sleep disturbance and obesity. J Clin Endocrinol Metab 1997, 82:1313-6.
• [21]American Diabetes Association: Diagnosis and classification of diabetes melittus Diabetes Care 2008, 31(Suppl 1):55-60.
• [22]Rechtschaffen A, Kales A: A manual of standardized terminology, techniques and scoring system and sleep stages of human subjects. University of California Brain Information Service, Los Angeles; 1968.
• [23]American Sleep Disorders Association: EEG arousals: scoring rules and examples: a preliminary report from the Sleep Disorders Atlas Task Force of the American Sleep Disorders Association Sleep 1992, 15:173-84.
• [24]American Academy of Sleep Medicine: Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The report of an American Academy of Sleep Medicine Task Force Sleep 1999, 22:667-89.
• [25]Johns MW: A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep 1991, 14:540-5.
• [26]Whicher JT, Ritchie RF, Johnson AM, Baudner S, Bienvenu J, Blirup-Jensen S, et al.: New international reference preparation for proteins in human serum (RPPHS). Clin Chem 1994, 40:934-8.
• [27]Pfeiffer CM, Huff D, Gunter EW: Rapid and accurate HPLC assay for plasma total homocysteine and cysteine in a Clinical Laboratory Setting. Clin Chem 1999, 45:290-2.
• [28]Gur M, Aslan M, Yildiz A, Demirbag R, Yilmaz R, Selek S, et al.: Paraoxonase and arylesterase activities in coronary artery disease. Eur J Clin Invest 2006, 36:779-87.
• [29]Sharma SK, Dakshinamurti K: Determination of vitamin B6 vitamin and pyridoxic acid in biological samples. J Chromatogr 1992, 578:45-51.
• [30]Lipid Research Clinics Program: Manual of laboratory operations vol 1: lipid and lipoprotein analysis. National Institutes of Health, Bethesda, Maryland; 1974.
• [31]Oliveira EP, Lima MDA, Souza MLA: Síndrome Metabólica, seus fenótipos e resistência à insulina pelo HOMA-RI. Arq Bras Endocrinol Metab 2007, 51:1506-15.
• [32]Guilleminault C, Kirisoglu C, Ohayon MM: C-reactive protein and sleep-disordered breathing. Sleep 2004, 27:1507-11.
• [33]Ryan S, Nolan GM, Hannigan E, Cunningham S, Taylor C, McNicholas WT: Cardiovascular risk markers in obstructive sleep apnoea syndrome and correlation with obesity. Thorax 2007, 62:509-14.
• [34]Vgontzas AN, Papanicolau DA, Bixler EO, Hopper K, Lotsikas A, Lin H, et al.: Sleep apnea and day time sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemia. J Clin Endocrinol Metab 2000, 85:1151-8.
• [35]Punjabi NM, Beamer BA: C-reactive Protein is associated with sleep disordered breathing independent of Obesity. Sleep 2007, 30:29-34.
• [36]Kokturk O, Ciftci TU, Mollarecep E, Ciftci B: Elevated C-reactive protein levels and increased cardiovascular risk in patients with obstructive sleep apnea syndrome. Int Heart J 2005, 46:801-8.
• [37]Young T, Finn L, Peppard PE, Szklo-Coxe M, Austin D, Javier Nieto F, et al.: Sleep disordered breathing and mortality: eighteen-year follow-up of the Wisconsin Sleep Cohort. Sleep 2008, 31:1071-8.
• [38]Lavie L, Vishnevsky A, Lavie P: Evidence of lipid peroxidation in obstructive sleep apnea. Sleep 2004, 27:123-8.
• [39]Xiao Y, Zhang Y, Lv X, Su D, Li D, Xia M, et al.: Relationship between lipid profile and plasma total homocysteine, cysteine and the risk of coronary artery disease in coronary angiographic subjects. Lipid Health Dis 2011, 10:137. BioMed Central Full Text
• [40]Refsum H, Ueland PM, Nygard O, Vollset SE: Homocysteine and cardiovascular disease. Annu Rev Med 1998, 49:31-62.
• [41]Kokturk O, Ciftci TU, Mollarecep E, Ciftci B: Serum homocysteine levels and cardiovascular morbidity in obstructive sleep apnea syndrome. Resp Med 2006, 100:536-41.
• [42]Lavie L, Perelman A, Lavie P: Plasma homocysteine levels in obstructive sleep apnea – association with cardiovascular morbidity. Chest 2001, 120:900-8.
• [43]Kono M, Tatsumi K, Saibara T, Nakamura A, Tanabe N, Takiguchi Y, et al.: Obstructive sleep apnea syndrome is associated with some components of metabolic syndrome. Chest 2007, 131:1387-92.